An aim in development of new antidepressants (ADs) now includes increasing speed of action. New drugs are tested primarily in outpatients who are less severely depressed than the patients treated in earlier trials of the tricyclic drugs. To determine early efficacy requires measures sensitive to initial changes in components of the illness as well as in the severity of the entire syndrome of depression. This paper describes the development of a brief 'multivantaged' (MV) method for assessing the major behavioural and affective components of depression. The revised Brief MV was significantly reduced from the original to make it more feasible to apply in outpatient studies. In this study we determined the Brief MV's (1) reliability and comparability to the original and (2) its ability to detect the onset of specific behavioural effects in outpatients treated with paroxetine for 6 wk. The latter is compared to the ability of the Hamilton Depression Scale (HAMD) to detect changes in global severity. The constructs derived from the Brief MV were found to be highly similar to those of the original version and as reliable. In depressed patients who responded to paroxetine, the HAMD and MV detected onset of improvement after 7 d of treatment. The Brief MV revealed that the improvement in global severity was due to the drug's action at this time on behaviours such as anxiety and distressed expression, as well as on a severity dimension of anxiety-agitation-somatization. Thus, the Brief MV, in uncovering underlying behavioural actions, represents an important addition to the current unidimensional HAMD approach in drug research.
Introduction
Despite many recent studies on their timing and sequence of actions (Gelenberg and Chesen, 2000) , the onset of the clinical actions of antidepressants (ADs) remains controversial. Almost all of these studies have used improvement in overall severity of the depressive disorder as the primary measure of onset and applied the Hamilton Depression Scale (HAMD ; Hamilton, 1960) to measure response at successive weekly timepoints. In accord with the goal of clinical trials of ADs, the HAMD and Montgomery-Asberg Depression Rating Scale (MADRS ; Montgomery and Asberg, 1979) are appropriate and adequately sensitive methods with which to measure changes in the overall therapeutic effect (i.e. severity of the disorder) during the course of treatment. There is evidence, however, from studies of the tricyclic ADs (TCAs) , that the process of recovery is initiated by discernible early changes in certain affective and behavioural components of the disorder that precede or underlie changes in the overall syndrome . The process involved reductions in the levels of hostility and anxiety within the first 10 d followed by decreases in motor retardation and other elements of the disorder. In a recent placebo-controlled study (Katz et al., 2004) similar results were obtained using the 'multivantaged ' (MV) method to detect early improvement in specific behavioural components of major depressive disorder (MDD) produced by either a selective serotonin reuptake inhibitor (SSRI) or selective noradrenergic reuptake inhibitor (SNRI) in the treatment of moderate to severely depressed, hospitalized patients. The initial timing and behavioural changes were different for the pharmacologically distinct ADs but occurred, as with the TCAs, in the first 2 wk of treatment. These studies also made it clear that in order to meet both clinical and scientific aims of research on the efficacy of new drugs, i.e. to uncover the timing, nature and mechanisms of action of ADs, the constructs of 'improvement ' and 'full response ' must first be distinguished, and more discrete measures of the components of the disorder, in addition to measures of overall severity, must be applied.
Information on onset, timing and the nature of clinical actions is now sought in trials of both new and established ADs. The original MV approach was designed for an in-patient setting and utilizes clinician and nurse ratings, patient self-report scales and psychomotor performance tests. It requires approx. 40 min for the doctor ratings, 30 min for those done by the nurse and 45 min for those completed by the patient in each of the initial behavioural and treatment assessment phases. The MV method was found in these earlier studies to uncover specific neurotransmitter metabolite-behavioural relationships in depression and in mania (Redmond et al., 1986 ; Swann et al., 1987) , associations between TCA-induced changes in serotonergic and noradrenergic systems and in specific but different behaviours (Katz et al., 1994) , to determine onset and sequence of behavioural actions in TCA-responsive patients and to distinguish the early clinical actions of pharmacologically different SSRI and SNRI ADs (Katz et al., 2004) . Since most new trials are carried out primarily in outpatient settings, we report in this paper the development of a revised briefer, more practical form of the MV method to be used in such settings. The general aim of this study was to test the feasibility and resolving power of a set of behavioural methods designed to measure the efficacy, onset and sequence of specific clinical actions of ADs. The specific aims were to (1) test if the behavioural constructs and dimensions of the Brief MV were comparable to those of the original MV and as reliable, and (2) evaluate if the method could detect early behavioural changes in depressed patients treated with a representative SSRI, namely paroxetine. It was found that the briefer, outpatient set of measurements is comparable in sensitivity to the more extensive set used for the in-patient studies.
Method
The patient sample was drawn from consecutive admissions for MDD at outpatient clinics in San Antonio (VA Hospital) and Houston (University of Texas Mental Sciences Institute). A baseline HAMD total score of o18 and assignment to treatment with an AD was required of study patients. Patients with comorbid anxiety disorders were excluded. Of the first 52 patients qualifying at the two clinics, 36 received paroxetine, and 16 received other ADs. The study was confined to the 36 patients receiving paroxetine, 20 admitted in San Antonio and 16 in Houston. The sample included 17 male and 19 female patients who ranged in age from 18 to 67 yr, with an average age of 40.8 yr. With respect to prior episodes, 26 % were first-episode depressions, and 74 % had one or more previous episodes. The average baseline 21-item HAMD total score (¡S.D.) was 23.7¡5.2 ; on the CGI, 68 % were rated as ' moderately ill ', 26 % as ' marked to severe '. One patient dropped out early in treatment.
The dosage for paroxetine ranged from 20 to 60 mg/d, with a target dose of 30 mg. Depending on side-effects and clinical response, it was adjusted upwards during the first 2 wk of the 6-wk course from 20 to 30 mg in accord with the clinician's practice with this agent. Following the second week, 80 % of patients were on 30 mg during the remaining 5 wk, but several had the dosage raised to 40 or to 60 mg later in the treatment course. To measure drug actions, the HAMD and a new brief version of the MV set (Brief MV) were applied twice weekly during the first 3 wk and once weekly during the remaining 3 wk. The scales used for the Brief MV are given in Table 1 as are the average times for administering these tests.
Key aspects of the differences between the full and briefer versions of the MV battery are that the nurses' rating scales are removed, as are 30 items from the SCL-90 (Derogatis et al., 1974) , 19 items from the NIMH Mood Scale (Raskin et al., 1969) , and the affective symptoms section of the Video Interview Behaviour Evaluation Scale (VIBES ; Katz et al., 1989) . Most of the items that are involved in the original factorial scoring of the latter three inventories and the Schedule for Affective Disorders -Change version (SADS-C ; Endicott and Spitzer, 1978) were retained. The scoring of the constructs in the Brief forms was, therefore, almost identical to that applied in the original longer forms of these tests. Outcome was measured at the end of 6 wk of treatment using the same categorical index for assigning patients that was used in the in-patient studies. It is based on combined criteria from improvement and final status ratings on the HAMD, Clinical Global Impression (CGI ; Guy, 1976) and Global Assessment Scale (GAS ; Endicott et al., 1976) . This index divided patients into ' clear responders ' (n=25), ' indeterminates ' (partial responders) (n=7), and 'nonresponders ' (n=3). Because of the small number of categorical non-responders, the course of drug action in clear responders was compared with that of the combined indeterminate and non-responders, designated as ' non-responders ' (n=10).
The MV battery, used to evaluate drug actions, combines scores from doctor ratings with scores from patient self-reports to derive measures of 11 components of the depressive disorder such as depressed mood, anxiety, hostility and distressed expression, as described previously (Katz et al., 1982 . In addition, three independent severity dimensions, comprised by combining constructs found by principal components analysis to be associated, i.e. anxiety-agitation-somatization-sleep disorder ; depressed mood-motor retardation (DM-MR), and hostility-interpersonal sensitivity were also measured .
Reliability and similarity of the revised Brief and original constructs
The revised Brief version did not include the nurses' rating methods and provided shorter self-report inventories in order to reduce time of administration. These revisions would increase its feasibility for use with outpatients but it would be necessary to determine if the componential measures derived from the revised vehicle were : (1) as reliable as those derived from the original instruments ; and (2) whether the new measures would make possible the discrimination of early AD-induced behavioural actions in treatment responders from those that occur in nonresponders.
Since each of the constructs contains ratings from several vantages, it was not expected that the elimination of one vantage (the nurses') would seriously impair the sensitivity of the construct. The data used to assess the psychometric characteristics of the revised battery was that provided by the NIMH Collaborative Study of the Psychobiology of Depression (Croughan et al., 1988 ; Maas et al., 1980) . Data from the original battery administered to 132 depressed patients (unipolar and bipolar), 20 manic patients and 80 healthy controls were available, including the values of the constructs and severity dimensions using the full MV. The revised battery was used to generate a parallel set of the same constructs. The items on the Brief versions of the instruments (Table 1) are subsets of the items on the full instruments. Therefore, it was possible to compute a parallel set of the same constructs for all MV behavioural method for onset of AD actions 473 by guest on November 4, 2016 http://ijnp.oxfordjournals.org/ patients from the Collaborative study. To test the similarity of scores, the baseline values for the constructs scored with the Brief version were correlated with the comparable values scored with the original. The same procedure was followed with patient values on the constructs after 2 wk of treatment.
Test-retest reliability
Analyses were carried out using the computed values for each patient for each construct during the pretreatment period, i.e. the time-period when the pathology would be most severe. The Collaborative study had a 2-wk placebo pre-treatment period. Since there was no active treatment during that period, there should be little change in the values. The correlations between pre-treatment days 3 and 10 and between pre-treatment days 10 and 15 were calculated and reliability was defined as the average of the two correlations.
Performance of the Brief MV method
To compare the two methods, analyses of the sensitivity of the MV severity dimensions and of the HAMD in detecting onset and early treatment-induced changes in SSRI responders were first conducted separately. To measure onset and rate of action, a mixed model analysis of variance (ANOVA, slopes test ; Laird and Ware, 1982) was applied to determine whether the rate of reduction in severity in the responder group was significantly more rapid during the first 16 d of treatment than for the 'non-responder ' group. If a difference in the rate of reduction was shown, then for each measure and treatment time-point, analysis of covariance (ANCOVA) at each time-point covarying for baseline value was run to identify the initial time-points at which the reduction of severity was significantly greater in the responder group. In analysing results using the Brief MV method, the focus was first on the three severity dimensions, and second, on constructs found to change within the first 2 wk in previous studies (Katz et al., , 2004 . These constructs include depressed mood, anxiety, hostility, motor retardation, distressed (physical) expression and sleep disorder. In order to measure the timecourse of change for treatment responders on the Brief MV behavioural and severity variables over the entire treatment period, survival analysis was also applied. The onset of 'improvement ' for a particular variable was defined according to Stassen et al. (1993) , as the initial time-point at which a reduction of o20 % occurs, which is then sustained throughout the course of the treatment. Onset of 'full response' would occur when a sustained reduction of o50 % occurs. To estimate 'onset ' of improvement and of full response, the median, that time-point when 50 % or more patients achieve the criterion, would be computed.
Results
The average baseline severity scores for the patient samples at San Antonio and Houston were similar, e.g. the HAMD scores were 22.4¡5.1 for San Antonio and 25.9¡5.0 for Houston (mean¡S.D.) respectively. The two samples were therefore, combined. Dividing the merged sample into two outcome groups based on response to treatment after 6 wk, resulted in sample sizes of 25 responders and 10 non-responders. Thus, more than 70 % of patients had a full response to the 6-wk course of SSRI treatment.
Comparability of the derived constructs from the Brief MV and from the original MV battery Table 2 provides the correlations between the Brief MV and the original MV of the baseline values of constructs. The product-moment correlations are high at both baseline and during treatment, all except the values for agitation, at 0.75 or higher. They are also significant for agitation but at the more modest levels of 0.51 and 0.57. Table 3 gives the correlations between baseline days for each of a set of constructs derived from the revised Brief battery and the reliability (average correlation). The reliability of these constructs is compared in Table 3 with the reliability of construct measures from the original battery. It can be seen from the set shown that, as expected, the Brief scale reliabilities are all 0.70 or higher. The average reliabilities of the two sets of constructs were, therefore, highly similar.
Reliability of the Brief constructs

Response to treatment with paroxetine
HAMD results
The total score significantly distinguished the two outcome groups on rate of reduction of severity during the first 16 d of treatment, as revealed by the mixed model, slopes analysis (p<0.02). The ANCOVA showed the reduction in severity to be greater in the responder than in the non-responder group at day 10 of treatment (p<0.05) and at day 13 (p<0.01) (Figure 1 ).
MV dimensions and constructs
Of the three severity dimensions, anxiety-agitationsomatization distinguished the rate of reduction in the responders during the first 16 d of treatment from the non-responders ( p<0.05). Reduction in the anxiety dimension was greater in responders, specifically at day 10 ( p<0.05) and day 13 ( p<0.01) (ANCOVA) (Figure 2 ). The two groups were not significantly different on the rates of reduction of the DM-MR and hostility dimensions. Further analyses of effects of treatment on the five component measures (those which have been shown in the in-patient studies to detect early drug actions) show the early actions which distinguish the responders and non-responders to be in the reduction of distressed physical expression at day 13 ( p<0.05) and in sleep disorder at day 10 ( p=0.055) and day 13 ( p<0.05) (Figure 3) .
The results of survival analysis of the improvement and full response data for the treatment responders on the Brief MV specific state and severity constructs and on the HAMD are shown in Table 4 . They indicate that the median time of onset of initial improvement in the Days of treatment Mean severity score Figure 1 . Time-course of change on the Hamilton Depression Scale : responders (-2-, n=25) vs. non-responders (-&-, n=10) to paroxetine. Paroxetine reduced overall severity of depression at a significantly faster rate during the first 2 wk in treatment responders than in nonresponders (slopes test, p<0.05). At day 10 (* p<0.05, ANCOVA) and day 13 (** p<0.01, ANCOVA). The improvement was significantly greater in responders than in non-responders. Although behavioural assessments were carried out at days 21, 28 and 35 of treatment, these time-points were not essential for the hypothesis being tested. Consequently, values obtained at these time-points are omitted from Figures 1-3 for clarity of the data presentation.
responders begins as early as 7 d on the anxietyagitation-somatization severity dimension (see Figure  4 ) and on the related specific constructs, anxiety, distressed depression and sleep disorder. It is also detected at 7 d through change in the overall severity of the syndrome, as reflected in the HAMD. The results of analysis of full response are in accord with the improvement findings, showing it to occur in half of the subjects at 16 d on anxiety and depressed expression, and on overall severity. These survival analysis findings agree in substance with those found applying analysis of covariance and the mixed model described above, but show a slightly more rapid onset of behavioural actions.
Discussion
There has been much research and controversy around the issue of how to measure the onset (Leon, 2001 ; Montgomery et al., 2002) and the nature of early clinical actions of ADs. Recent research has produced evidence counter to the notion that there is a time lag of several weeks between the almost immediate neurochemical actions of the drugs and changes in clinical behaviour (Gelenberg and Chesen, 2000 ; Katz et al., 1996 Katz et al., /1997 Parker et al., 2000) . The most comprehensive work on the issue using the HAMD total score as the measure of change, has been conducted by Stassen et al. (1997) . They have distinguished between 'improvement ' (o20 % reduction, sustained throughout the course of treatment) and 'full response' (o50 % sustained change). They then showed in a metaanalysis that initial improvement for most ADs tested occurred on average at 13 d and full response at 20 d.
The original MV detected greater behavioural changes induced by the TCAs in treatment-responsive depressed in-patients than in non-responders within the first 2 wk of treatment . The state (-2-, n=25) vs. non-responders (-&-, n=10) to paroxetine. Paroxetine reduced the severity of the anxiety-agitation-somatization dimension at a significantly faster rate during the first 2 wk in responders than in non-responders (slopes test, p<0.05). At day 10 (* p<0.05, ANCOVA) and day 13 (** p<0.01, ANCOVA) the improvement in the anxiety dimension was significantly greater in responders than in non-responders. Onset : time-point (days of treatment) at which o50 % of patients show o20 % of positive change on behavioural measure (improvement) or o50 % change (full response) which is sustained through 6 wk of treatment. DM-MR, Depressed mood-motor retardation.
constructs derived from the original MV have also been demonstrated to be sensitive to early behavioural change in a recently completed placebo-controlled inpatient study which examined the onset, timing and nature of the behavioural actions of paroxetine and desipramine (Katz et al., 2004) . This current study showed that the constructs derived from the Brief MV were as reliable as those found in the original. Also, the Brief MV generated construct values highly similar to those that would be obtained with the original form. Thus, the Brief MV was demonstrated to be psychometrically sound in providing values comparable to the original and likely to approximate its sensitivity in detecting early AD effects.
The second part of this study evaluated the ability of the Brief MV to detect actions of paroxetine in outpatients within the first 2 wk in treatment-responsive patients, and to characterize the nature of its initial behavioural actions. In outpatients who responded to paroxetine after 6 wk of treatment, the HAMD detected improvement in overall severity within the first 2 wk of treatment and survival analysis indicated the median time of onset of improvement in overall severity to occur in such patients by 7 d. The Brief MV also detected improvement early in eventual responders to paroxetine and further identified specific behaviours which improved early and which did not. The early global improvement in the syndrome of depression caused by paroxetine was shown to be driven by early improvement in the dimension of anxietyagitation-somatization as well as in specific behaviours such as distressed expression and sleep disorder.
Thus, the unique information contributed by the Brief MV method in clinical trials is in its capacity to delineate drug-induced actions on specific behaviours or affects that although not detectable through use of the HAMD total severity score, are responsible for initiating the therapeutic process. It appears that if a methodological approach, as detailed as the Brief MV, had been applied in the beginning trials of paroxetine, its efficacy as an 'anxiolytic ' agent, later demonstrated in a series of studies (Gorman, 2000 ; Lydiard and Bobes, 2000 ; Pollack et al., 2001) , would have been established many years earlier.
Further, the method's capacity to separate effects on various major components of the disorder provides an important methodological strength in attacking problems central to understanding how antidepressants work, i.e. uncovering underlying neurobehavioural mechanisms of drug action. Thus, as noted earlier, the MV method permits determining which behaviours are associated with changes in the functioning of specific neurotransmitter systems. Determining the behavioural changes that initiate the therapeutic process makes it particularly useful in linking initial neurochemical actions of the drug to specific behavioural and affective changes (Katz et al., 2004 ). It also makes it possible to identify specific early behavioural changes that are predictive of clinical outcome.
Conclusions
(1) The Brief MV generates constructs that are similar to those of the original MV and are just as reliable. (2) The Brief MV assessment of the components of the depressive disorder identifies the early actions of paroxetine in treatment-responsive patients as the reduction of anxiety, distressed (physical) expression and sleep disorder. Thus, the method is able to provide information on the specific behavioural changes that underlie the drug's efficacy. (3) The Brief MV, considerably reduced in length to make it more practical for application in outpatient settings, provides a comprehensive and sensitive approach to detecting onset, nature and sequence of the early clinical actions of established ADs. By describing the profile, timing and sequence of clinical actions it is particularly well suited for research designed to uncover applications to other psychiatric disorders for which ADs might be appropriate.
